Home > Press > IQ Micro Presents at NSTI Nanotechnology Conference
IQ Micro Inc. (OTCBB: IQMC), exclusive licensor of electro-osmotic membranes and micro-pumps for the rapidly emerging microfluidic technology sector, announced today that it will give two presentations at the 10th annual NSTI Nanotechnology Conference and Trade Show and at the TechConnect Summit in Santa Clara Convention Center, Santa Clara, CA, on May 20-24, 2007.
IQ Micro Presents at NSTI Nanotechnology Conference
WEST PALM BEACH, FL | Posted on May 22nd, 2007
On May 23rd, IQ Micro Senior Scientist Trond Heldal will present, "Embeddable Low-Voltage Micropump using Electroosmosis of the Second Kind" under the "Micro & Nano Fluidics: Transport & Dispersion" session. On May 24th, Mr. Heldal will also present "Microfluidic pump and actuators" during the TechConnect Summit.
IQ Micro President and CEO Johnny Christiansen said, "The NSTI conference is the premier meeting place for research and businesses within the micro- and nanotechnology sector, and we are pleased that IQ Micro's technology has been accepted for two presentations at this year's conference."
About The NSTI Nanotechnology Conference and Trade Show
Since 1998, the NSTI Nanotechnology Conference and Trade Show has grown in both scope and audience. Last year's event attracted 3,000 worldwide attendees. The NSTI nanotechnology conference and trade show now ranks as the largest international nanotechnology conference in the world, focusing not only on scientists and researchers, but also on investors, venture capitalists and business executives interested in the ways that nanotechnology can drive business in the 21st century.
About IQ Micro Inc.
IQ Micro Inc. ( http://www.iq-micro.com ) is an international licensing company that commercializes proprietary technology developed for use in the microfluidics sector. Developed from the micro-chip industry, microfluidics involves circuits of tiny chambers, channels and pumps that direct the flow of liquids on a single micro-chip.
IQ Micro is actively pursuing global licensing opportunities for its patented electro-osmotic membrane technology and its "invisible pump," a microfluidic technology with a wide range of consumer, medical and industrial applications. With its proprietary technology and highly experienced management, IQ Micro expects to become a leading global, specialized supplier of low-voltage microfluidic technology.
The recent Osmotex/Lifecare merger is expected to result in an expanded licensing arrangement with IQ Micro, which will include the exclusive sales and marketing rights to Lifecare's implantable, osmotic sensor for use in diabetes monitoring.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. The words "may," "could," "should," "believe," "anticipate," "estimate," "expect," "intend," "plan" and similar words are intended to identify forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third-party manufacturers to produce components on a basis which is cost-effective to the company, our ability to protect our intellectual property rights from infringement by third parties, our ability to convert our intellectual property rights into product offerings that are accepted by the market, the development of competitors of intellectual property and associated products that are superior to ours or that gain better market acceptance than ours and the ability of our intellectual property rights to keep pace with the advances in technology, market acceptance of the company's products and licensing rights, the effects of government regulation and other factors. Results actually achieved may differ materially from expected results included in these statements. The company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Furthermore, this company cautions that the risk factors listed in this paragraph are not exhaustive.
For more information, please click here
D.P. Martin & Associates
Investor Relations for IQ Micro
Copyright © Market Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014
Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014
'Exotic' material is like a switch when super thin April 18th, 2014
Innovative strategy to facilitate organ repair April 18th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Nanoparticles cause cancer cells to self-destruct April 3rd, 2014
A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014
Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014
INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014
'Life Redesigned: The Emergence of Synthetic Biology' Lecture at Brookhaven Lab on Wednesday, April 30: Biomedical Engineer James Collins to Speak for BSA Distinguished Lecture Series April 16th, 2014
ECHA Planning Workshop on Regulatory Challenges in the Risk Assessment of Nanomaterials April 16th, 2014
Engineers develop new materials for hydrogen storage April 15th, 2014